Search Results - "Villé, Jade"
-
1
327 Humanized mouse models for characterizing growth and tissue infiltration of luciferase-expressing AML cell lines
Published in Journal for immunotherapy of cancer (01-11-2023)“…BackgroundLeukemia, notably Acute Myeloid Leukemia (AML), a prominent subtype, is a major health concern worldwide, marked by high mortality rates. Despite the…”
Get full text
Journal Article -
2
Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer
Published in BMC immunology (04-12-2019)“…High-dose intravenous immunoglobulin (IVIg), and more recently, subcutaneously-delivered Ig (SCIg), are used to treat a variety of autoimmune diseases;…”
Get full text
Journal Article -
3
Abstract 3960: Establishment of humanized mouse models engrafted with luciferase-expressing acute myeloid leukemia cell lines
Published in Cancer research (Chicago, Ill.) (22-03-2024)“…Abstract Introduction: Because acute myeloid leukemia (AML) is a very aggressive and quickly developing cancer, for which actual treatments are either…”
Get full text
Journal Article -
4
Abstract 4594: Induction of apoptosis by anti-CD20 antibodies requires the induction of EGR-1 and calcium influx
Published in Cancer research (Chicago, Ill.) (01-07-2017)“…Abstract Background: Anti-CD20 monoclonal antibodies (mAbs) are an essential component of the treatment of patients with CD20-positive non-Hodgkin's lymphoma…”
Get full text
Journal Article -
5
Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction
Published in Molecular cancer therapeutics (01-11-2020)“…Direct cell death induction, in addition to immune-effector cell-mediated mechanisms, is one of the key mechanisms of action of anti-CD20 antibodies, and yet…”
Get full text
Journal Article -
6
Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-[mu]TP-L309C, a recombinant IgG1 Fc hexamer
Published in BMC immunology (04-12-2019)“…High-dose intravenous immunoglobulin (IVIg), and more recently, subcutaneously-delivered Ig (SCIg), are used to treat a variety of autoimmune diseases;…”
Get full text
Journal Article